^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    J Thorac Oncol
    Title:

    OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

    Excerpt:
    In the Phase 3 MYSTIC study (NCT02453282), blood tumour mutational burden, at various thresholds from ≥12 to ≥20 mut/Mb (bTMB≥20), has been associated with improved OS and PFS with first-line durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) versus platinum-based chemotherapy (CT). Specific gene mutations have been associated with resistance (STK11 and KEAP1) or sensitisation (ARID1A) to anti-PD-(L)1 monotherapy.
    DOI:
    10.1016/j.jtho.2019.08.428